No Data
No Data
No Data
No Data
No Data
Biotech (688177.SH) announced first-quarter results with a net loss of 119 million yuan
Biotech (688177.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 1...
Zhitong FinanceApr 29 19:27
Express News | Biotech: tocilizumab injections received positive opinions from the European Medicines Agency's Human Medicines Committee
BreakingsApr 26 16:04
Private Companies Among Bio-Thera Solutions, Ltd.'s (SHSE:688177) Largest Stockholders and Were Hit After Last Week's 12% Price Drop
Key Insights The considerable ownership by private companies in Bio-Thera Solutions indicates that they collectively have a greater say in management and business strategy A total of 4 investors hav
Simply Wall StApr 19 07:59
Pacific released a research report on April 16 stating that it gave Biotai (688177.SH) a purchase rating. The main reasons for the rating include: 1) self-exemption and anti-tumor drugs drive rapid revenue growth; 2) multiple biosimilar drugs go overseas
Pacific released a research report on April 16 stating that it gave Biotai (688177.SH) a purchase rating. The main reasons for the rating include: 1) self-exemption and anti-tumor drugs drive rapid revenue growth; 2) multiple biosimilar drugs go overseas to contribute to revenue flexibility; 3) the smooth progress of the innovative drug pipeline. (Mainichi Keizai Shimbun)
Zhitong FinanceApr 16 10:12
Express News | Many biomedical companies “took U” and then lost money
BreakingsApr 10 08:08
Biotech (688177): Biosimilar drugs have entered the harvest period and the ADC pipeline continues to advance
Baiaotai Co., Ltd. announced that in 2023, the company achieved operating revenue of 705 million yuan, an increase of 54.86% over the previous year. Net profit attributable to owners of the parent company - 395 million yuan, a decrease of 17 percent from the previous year's loss.
華鑫證券Apr 9 07:51
No Data
No Data